- Home
- STRO vs BNTC Comparison
STRO vs BNTC Comparison
Compare STRO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | BNTC |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 454.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | STRO | BNTC |
|---|---|---|
| Price | $22.94 | $11.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $31.33 | $27.67 |
| AVG Volume (30 Days) | ★ 441.4K | 120.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $9.85 |
| 52 Week High | $43.85 | $16.76 |
Technical Indicators
Market Signals| Indicator | STRO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 40.83 |
| Support Level | $19.11 | $11.40 |
| Resistance Level | $27.96 | $13.48 |
| Average True Range (ATR) | 2.14 | 0.71 |
| MACD | -0.55 | -0.25 |
| Stochastic Oscillator | 10.83 | 19.99 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.